SeqOnce is accelerating life science discoveries and improving patient outcomes by focusing on Next Gen Sequencing for genomics and diagnostics. We believe optimizing kit chemistries unlocks hidden potentials in existing platforms.
Real-world solutions for real-world science.
Founded in 2014, SeqOnce was spun out of USC and is privately held. The founders have complementary skill sets with CSO Joseph Dunham’s strong background in molecular biology and technology development, James Gilmore in molecular biology and commercialization, and CEO Chris Angermayer’s expertise in finance and operations. SeqOnce is growing rapidly as it continues to launch new products in genomics and diagnostics.
SeqOnce’s leading genomics commercial product slashes Next Gen Sequencing preparation time over 75% compared to other kits, while also vastly simplifying the protocol to only three steps. For diagnostics, AzureSeq provides reliable results with significant time savings.
Want to accelerate your Illumina Sequencer or your CLIA lab? How about your career?